UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2024
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
BLOCK LISTING SIX MONTHLY RETURN
Date: 13 November 2024
Name of applicant: | GSK plc |
Name of scheme: | GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan |
Period of return: | From: | 1 May 2024 | To: | 31 October 2024 |
Balance of unallotted securities under scheme(s) from previous return: | 115,518 |
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 |
Less: Number of securities issued/allotted under scheme(s) during period (see UKLR 20.6.7G): | 0 |
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 115,518 |
Name of applicant: | GSK plc |
Name of scheme: | GlaxoSmithKline plc Share Save Plan 2012 |
Period of return: | From: | 1 May 2024 | To: | 31 October 2024 |
Balance of unallotted securities under scheme(s) from previous return: | 673,024 |
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 |
Less: Number of securities issued/allotted under scheme(s) during period (see UKLR 20.6.7G): | 155,786 |
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 517,238 |
Name of applicant: | GSK plc |
Name of scheme: | GlaxoSmithKline plc Share Save Plan 2022 |
Period of return: | From: | 1 May 2024 | To: | 31 October 2024 |
Balance of unallotted securities under scheme(s) from previous return: | 995,257 |
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 |
Less: Number of securities issued/allotted under scheme(s) during period (see UKLR 20.6.7G): | 19,867 |
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 975,390 |
Name of contact: | Victoria Whyte |
Telephone number of contact: | 020 8047 5000 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| | GSK plc |
| | (Registrant) |
| | |
| Date: November 13, 2024 | |
| | |
| | By:/s/ VICTORIA WHYTE -------------------------- |
| | |
| | Victoria Whyte |
| | Authorised Signatory for and on |
| | behalf of GSK plc |
